CD40 Ligand antibody

Catalog No. ABIN1176849

Product Details anti-CD40 Ligand Antibody

Target: CD40 Ligand (CD40LG)

Reactivity: Mouse

Host: Armenian Hamster

Clonality: Monoclonal

Conjugate: This CD40 Ligand antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Blocking Reagent (BR)

Brand: BD Pharmingen™

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level: Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Activated mouse Th1 clone D1.6

Clone: MR1

Isotype: IgG3 kappa

Application Details

Application Notes: Flow cytometry: For the detection of mouse CD154 on activated peripheral T cells, it is strongly recommended that T cells be purified before activation. Mouse CD154 is transiently expressed on the surfaces of activated normal T cells and certain T cell clones with a maximal level detected 6-8 hours post-activation. Activation with immobilized anti-CD3e mAb (e.g., 145-2C11, Cat. No. 557306/553058, or 500A2, Cat. No. 553238) is sufficient to induce CD154 expression on CD4+ cells. It has been reported that CD8+ cells express CD154 only in response to PMA/Ionomycin treatment. Therefore, for detection of CD154, it is crucial to utilize the proper activation stimuli and to stain cells at the optimal time for CD154 expression. We recommend the use of biotinylated mouse anti-hamster IgG cocktail (Cat. No. 554010) followed by a bright second-step reagent, such as Streptavidin-PE (Cat. No. 554061), for optimal detection of CD154.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.

Preservative: Azide free

Storage: 4 °C

Storage Comment: Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

References for anti-CD40 Ligand antibody (ABIN1176849)

Miga, Masters, Durell, Gonzalez, Jenkins, Maliszewski, Kikutani, Wade, Noelle: "Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions." in: European journal of immunology, Vol. 31, Issue 3, pp. 959-65, (2001) (PubMed).

Graca, Honey, Adams, Cobbold, Waldmann: "Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 165, Issue 9, pp. 4783-6, (2000) (PubMed).

Lettesjö, Burd, Mageed: "CD4+ T lymphocytes with constitutive CD40 ligand in preautoimmune (NZB x NZW)F1 lupus-prone mice: phenotype and possible role in autoreactivity." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 165, Issue 7, pp. 4095-104, (2000) (PubMed).

Tomura, Yu, Ahn, Yamashita, Yang, Ono, Hamaoka, Kawano, Taniguchi, Koezuka, Fujiwara: "A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 163, Issue 1, pp. 93-101, (1999) (PubMed).

Garside, Ingulli, Merica, Johnson, Noelle, Jenkins: "Visualization of specific B and T lymphocyte interactions in the lymph node." in: Science (New York, N.Y.), Vol. 281, Issue 5373, pp. 96-9, (1998) (PubMed).

Grewal, Flavell: "CD40 and CD154 in cell-mediated immunity." in: Annual review of immunology, Vol. 16, pp. 111-35, (1998) (PubMed).

Kalled, Cutler, Datta, Thomas: "Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 160, Issue 5, pp. 2158-65, (1998) (PubMed).

Carbone, Ruggiero, Terrazzano, Palomba, Manzo, Fontana, Spits, Kärre, Zappacosta: "A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction." in: The Journal of experimental medicine, Vol. 185, Issue 12, pp. 2053-60, (1997) (PubMed).

DeKruyff, Gieni, Umetsu: "Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 158, Issue 1, pp. 359-66, (1997) (PubMed).

Kelsall, Stüber, Neurath, Strober: "Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses." in: Annals of the New York Academy of Sciences, Vol. 795, pp. 116-26, (1997) (PubMed).

Dunn, Luedecker, Haugen, Clegg, Farr: "Thymic overexpression of CD40 ligand disrupts normal thymic epithelial organization." in: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, Vol. 45, Issue 1, pp. 129-41, (1997) (PubMed).

Kawano, Cui, Koezuka, Toura, Kaneko, Motoki, Ueno, Nakagawa, Sato, Kondo, Koseki, Taniguchi: "CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides." in: Science (New York, N.Y.), Vol. 278, Issue 5343, pp. 1626-9, (1997) (PubMed).

Masten, Yates, Pollard Koga, Lipscomb: "Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L." in: American journal of respiratory cell and molecular biology, Vol. 16, Issue 3, pp. 335-42, (1997) (PubMed).

Griggs, Agersborg, Noelle, Ledbetter, Linsley, Tung: "The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells." in: The Journal of experimental medicine, Vol. 183, Issue 3, pp. 801-10, (1996) (PubMed).

Laman, Claassen, Noelle: "Functions of CD40 and its ligand, gp39 (CD40L)." in: Critical reviews in immunology, Vol. 16, Issue 1, pp. 59-108, (1996) (PubMed).

Larsen, Elwood, Alexander, Ritchie, Hendrix, Tucker-Burden, Cho, Aruffo, Hollenbaugh, Linsley, Winn, Pearson: "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways." in: Nature, Vol. 381, Issue 6581, pp. 434-8, (1996) (PubMed).

Tian, Noelle, Lawrence: "Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1." in: European journal of immunology, Vol. 25, Issue 1, pp. 306-9, (1995) (PubMed).

Foy, Page, Waldschmidt, Schoneveld, Laman, Masters, Tygrett, Ledbetter, Aruffo, Claassen, Xu, Flavell, Oehen, Hedrick, Noelle: "An essential role for gp39, the ligand for CD40, in thymic selection." in: The Journal of experimental medicine, Vol. 182, Issue 5, pp. 1377-88, (1995) (PubMed).

Roy, Aruffo, Ledbetter, Linsley, Kehry, Noelle: "Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses." in: European journal of immunology, Vol. 25, Issue 2, pp. 596-603, (1995) (PubMed).

Foy, Laman, Ledbetter, Aruffo, Claassen, Noelle: "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory." in: The Journal of experimental medicine, Vol. 180, Issue 1, pp. 157-63, (1994) (PubMed).

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: CD154 (CD40LG Products)

Synonyms: CD154 antibody, cd40l antibody, CD40L antibody, HIGM1 antibody, IGM antibody, IMD3 antibody, T-BAM antibody, TNFSF5 antibody, TRAP antibody, gp39 antibody, hCD40L antibody, CD40-L antibody, Cd40l antibody, Ly-62 antibody, Ly62 antibody, Tnfsf5 antibody, CD40 ligand antibody, TNF superfamily member 5 antibody, CD40LG antibody, cd40l antibody, Cd40lg antibody

Background: The MR1 antibody reacts with CD154 (CD40 Ligand, gp39), an accessory molecule expressed on activated T helper (CD4+) lymphocytes. CD154 has also been detected on other types of leukocytes, including CD8+ T cells, medullary thymocytes, activated CD4+ NK-T cells, and human NK cells. CD154 plays an important role in costimulatory interactions between T and B lymphocytes and between antigen-presenting cells and lymphocytes, regulating the immune response at multiple levels. MR1 mAb inhibits in vitro activation of B lymphocytes by T helper cells by blocking interaction of gp39 with CD40. In vitro interactions of T cells and antigen-presenting cells can also be blocked by the MR1 antibody. In vivo treatment with MR1 antibody blocks the development of experimental autoimmune disease, inhibits formation of germinal centers and generation of memory B cells, reduces T-lymphocyte responses to allogeneic cells and allografts, prevents intrathymic deletion of self-reactive T lymphocytes, and disrupts antigen-specific T-cell responses. CD154 expression on activated and resting T lymphocytes. BALB/c spleen T cells, purified on a T Cell Enrichment Column (R&D Systems), were cultured for 8 hours in the presence (Panels A and C) or absence (Panels B and D) of plate-bound 500A2 antibody (anti-CD3e, Cat. No. 553238). They were stained with NA/LE™ MR1 antibody (Panels A and B), followed by biotinylated mouse anti-hamster IgG, Cat. No. 554010, then Streptavidin-PE, Cat. No. 554061, (Panels A, B, C, and D). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Synonyms: CD40 Ligand, gp39

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints